Resverlogix expands Phase IIb apabetalone trial for Covid-19
Five more study centres in Brazil as well as a third Canadian site in Toronto, Ontario will become operational soon.

Five more study centres in Brazil as well as a third Canadian site in Toronto, Ontario will become operational soon.
The trial will assess the safety and efficacy of up to three intravenous doses of COVI-MSC administered on alternate days.
The trial to assess the efficacy and safety of apabetalone will enrol 100 subjects at centres in Canada and Brazil.
The trial will enrol 90 subjects to assess the safety, tolerability, and immunogenicity of three dose levels of the vaccine.
The trial plans to enrol approximately 1,600 Covid-19 patients, with recruitment progressing at 12 trial centres in Brazil.
Healthcare provision markets of middle-income countries are set to climb at an average annual rate of 5.7% in the next…
ByThe Brazilian trial will enrol 316 critically ill Covid-19 patients in hospital and require supplemental oxygen.
The trial will analyse the safety and efficacy of PSJ-539 in newly diagnosed Covid-19 patients.